PharmaShots Weekly Snapshot (January 13-17, 2020)

1. Arena’s APD418 Receives FDA’s Fast Track Designation to Treat Patients with Decompensated Heart Failure

Published: Jan 17, 2020 | Tags: Arena, APD418, Receives, FDA, Fast Track Designation, Treat, Patients, Decompensated Heart

2. Charles River Collaborates with Fios Genomics for Bioinformatics-Driven Drug Discovery and Safety Assessment

Published: Jan 16, 2020 | Tags: Charles River, Collaborates, Fios Genomics, Bioinformatics-Driven, Drug Discovery, Safety Assessment

3.  Healthy.io Launches Digital Wound Management Solution to Treat Chronic Wounds

Published: Jan 15, 2020 | Tags: Health.io, Launches, Digital Wound Management Solution, Evaluate, Chronic Wounds

4.  Just – Evotec Signs a Development and Manufacturing Agreement with OncoResponse for OR2805

Published: Jan 16, 2020 | Tags: Just – Evotec, Signs, Development, Manufacturing, Agreement, OncoResponse, OR2805

5. Novo Nordisk’s Ozempic (semaglutide) Receives the US FDA’s Approval for Reduction in MACE in Patients with Type 2 Diabetes

Published: Jan 16, 2020 | Tags: Novo Nordisk, Ozempic, semaglutide, Receives, US, FDA, Approval, Reduction, MACE, Patients, Type 2 Diabetes

6.  BioNTech To Acquire Neon to Bolster its Immunotherapy Pipeline

Published: Jan 16, 2020 | Tags: BioNTech, Acquire, Neon, Bolster, Immunotherapy Pipeline

7. Sun Pharma Signs a License Agreement with Rockwell Medical for Triferic in India

 Published:  Jan 15, 2020 | Tags: Sun Pharma, Signs, License Agreement, Rockwell Medical, Triferic, India 

8. BMS Reports the US FDA Acceptance of sBLA for Opdivo (nivolumab) + Yervoy (ipilimumab) as 1L Treatment for Non-Small Cell Lung Cancer

Published: Jan 15, 2020 | Tags: BMS, Reports, US, FDA, Acceptance, sBLA, Opdivo, nivolumab, Yervoy, ipilimumab, 1L, Treatment, Non-Small Cell Lung Cancer

9.  UCB’s Cimzia (certolizumab pegol) Receives Health Canada Approval for Non-Radiographic Axial Spondyloarthritis

Published: Jan 15, 2020 | Tags: UCB, Cimzia, certolizumab pegol, Receives, Health Canada Approval, Non-Radiographic Axial Spondyloarthritis

10.  Wuxi Biologic to Acquire Bayer’s Production Facility in Germany

Published: Jan 16, 2020 | Tags: Wuxi Biologic, Acquire, Bayer, Production Facility, Germany

11.  Livongo to Integrate Dexcom’s G6 CGM System into its Applied Health Signals Platform

Published: Jan 13, 2020 | Tags: Livongo, Integrate, Dexcom, G6 CGM System, Applied, Health Signals Platform

12. JT Signs an Exclusive License Agreement with Dermavant to Develop and Commercialize Tapinarof in Japan

Published: Jan 15, 2020 | Tags: JT, Signs, Exclusive, License Agreement, Dermavant, Develop, Commercialize, Tapinarof, Japan

13. Galapagos Signs an Exclusive Option to License Agreement with Fibrocor to Expand their Existing 2019 Partnership for Fibrosis

Published: Jan 15, 2020 | Tags: Galapagos, Expands, Existing, 2019, Collaboration, Fibrocor, Fibrosis

14. BioLineRx’s Motixafortide (BL-8040) Receives EC’s ODD to Treat Pancreatic Cancer in Europe

Published: Jan 14, 2020 | Tags: BioLineRx, Motixafortide, BL-8040, Receives, EC, ODD, Treat, Pancreatic Cancer, Europe

15. Kymera Signs a DNA-Encoded Library Based Drug Discovery Research Agreement with HitGen

Published: Jan 15, 2020 | Tags:  Kymera, Signs, DNA-Encoded Library, Drug Discovery, Research Agreement, HitGen

16.  Alexion to Initiate P-III CHAMPION-ALS Study Evaluating Ultomiris (ravulizumab) in Amyotrophic Lateral Sclerosis

Published: Jan 14, 2020 | Tags: Alexion, Initiate, P-III, CHAMPION-ALS, Study, Evaluating, Ultomiris, ravulizumab, Amyotrophic Lateral Sclerosis

17. JAMP Signs an Agreement with Alvotech to Commercialize Five Biosimilars in Canada

Published: Jan 14, 2020 | Tags: JAMP, Signs, Agreement, Alvotech, Commercialize, Five Biosimilars, Canada

18.  Insilico Collaborates with Pfizer to Explore Novel Data and AI System for Target Discovery

Published: Jan 14, 2020 | Tags: Insilico, Collaborates, Pfizer, Explore, Novel Data, AI System, Target Discovery

19.  ViiV Healthcare’s Dovato (dolutegravir/lamivudine) Receives MHLW’s Approval to Treat HIV 1 Infection

Published: Jan 15, 2020 | Tags: ViiV Healthcare, Dovato, dolutegravir/lamivudine, Receives, MHLW, Approval, HIV 1 Infection

20. Astellas’ Xospata (gilteritinib) Receives Health Canada Approval for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

Published: Jan 14, 2020 | Tags: Astellas, Xospata, gilteritinib, Receives, Health Canada, Approval, Relapsed, Refractory, Acute Myeloid Leukemia, FLT3 Mutation

21. Genome & Company Signs a Clinical Trial Agreement with Merck KGaA and Pfizer to Evaluate the Combination Therapy

Published: Jan 13, 2020 | Tags: Genome & Company, Signs, Clinical Trial Agreement, Merck KGaA, Pfizer, Evaluate, Combination Therapy

22.  Takeda Collaborates with Charles River to Identify and Develop Preclinical Candidates

Published: Jan 13, 2020 | Tags: Takeda, Collaborates, Charles River, Identify, Develop, Preclinical Candidates

23. Bayer Signs an Exclusive Option to License Agreement with Dare Biosciences to Commercialize Ovaprene in the U

Published: Jan 13, 2020 | Tags:  Bayer, Dare Biosciences, Signs, Exclusive, Option to License, Agreement, Commercialize, Ovaprene, US

24.  Axsome In-Licenses Pfizer’s Reboxetine and Esreboxetine in the US

Published: Jan 13, 2020 | Tags: Axsome, In-Licenses, Pfizer, Reboxetine, Esreboxetine, US

25. Amgen Collaborates with Guardant Health and Qiagen to Expand Molecular Testing for Patients with Non-Small Cell Lung Cancer

Published: Jan 14, 2020 | Tags: Amgen, Collaborates, Guardant Health, Qiagen, Expand, Molecular Testing, Patients, Non-Small Cell Lung Cancer

26.  Astellas and Adaptimmune Signs Co-Exclusive Agreement for Universal Donor Cell Platform and Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies

Published: Jan 14, 2020 | Tags: Astellas, Adaptimmune, Collaborate, Co-Develop, Co-Commercialize, Stem-Cell Derived Allogeneic, CAR-T, TCR, T-Cell Therapies

27. Roche Collaborates with Illumina to Expand the Adoption of NGS Based Testing in Oncology

Published: Jan 13, 2020 | Tags: Roche, Collaborates, Illumina, Broaden, Adoption, NGS Based Testing, Oncology

28. MSD Signs a Multiyear Agreement with Just – Evotec Biologics for Gaining Access to J.POD Facility

Published: Jan 14, 2020 | Tags: MSD, Signs, Multiyear Agreement, Just – Evotec Biologics, Gaining, Access, J.POD Facility

29. Coherus Signs a License Agreement with Innovent Biologics to Commercialize Biosimilar of Avastin (bevacizumab) in the US and Canada

Published: Jan 14, 2020 | Tags: Coherus, Signs, License Agreement, Innovent Biologics, Commercialize, Biosimilar, Avastin, bevacizumab, US, Canada

30. BeiGene Collaborates with EUSA Pharma to Develop and Commercialize Sylvant (siltuximab) and Qarziba (dinutuximab beta) in Greater China

Published: Jan 13, 2020 | Tags: BeiGene, Collaborates, EUSA Pharma, Develop, Commercialize, Sylvant, siltuximab, Qarziba, dinutuximab beta, Greater China

31. Biogen to Acquire Pfizer’s PF-05251749 to Bolster its Neurological Pipeline

Published: Jan 13, 2020 | Tags: Biogen, Acquire, Pfizer, PF-05251749, Bolster, Neurological Pipeline

32. Mundipharma Collaborates with Samsung Bioepis to Commercialize Multiple Biosimilar Candidates in Hong Kong and Taiwan

Published: Jan 12, 2020 | Tags: Mundipharma, Collaborates, Samsung Bioepis, Commercialize, Multiple, Biosimilar Candidates, Hong Kong, Taiwan

33. Roche Signs a Technology License Agreement with Amunix Pharmaceutical to Develop Non-Oncology Therapies

Published: Jan 10, 2020 | Tags: Roche, Signs, Technology, License Agreement, Amunix Pharmaceutical, Develop, Non-Oncology Therapeutics

34. Incyte Signs a Worldwide License Agreement with MorphoSys for Tafasitamab

Published: Jan 13, 2020 | Tags: Incyte, Signs, Worldwide, License Agreement, MorphoSys, Tafasitamab

35. AstraZeneca’s Lynparza (olaparib) + Bevacizumab Receive the US FDA’s Priority Review for 1L Treatment of Advanced Ovarian Cancers

Published: Jan 13, 2020 | Tags: AstraZeneca, Lynparza, olaparib, Bevacizumab, Receive, US, FDA, Priority Review, 1L, Treatment, Advanced Ovarian Cancers

36. Iovance Signs a License Agreement with Novartis to Develop and Commercialize IOV-3001

Published: Jan 12, 2020 | Tags: Iovance, Signs, License Agreement, Novartis, Develop, Commercialize, IOV-3001

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post